266
Views
4
CrossRef citations to date
0
Altmetric
Research Article

An improved synthesis of lysosomal activated mustard prodrug for tumor-specific activation and its cytotoxic evaluation

, , , &
Pages 1047-1053 | Received 26 Apr 2011, Accepted 31 Oct 2011, Published online: 20 Dec 2011

References

  • Rang HP, Dale MM, Ritter JM, Moore PK. (2003). Cancer Chemotherapy. Pharmacology. 5th ed. Oxford: Churchill Livingstone, 693–707.
  • Spinger CJ, Duvaz IN. (1995). Antibody-directed enzyme prodrug therapy (ADEPT) with mustard prodrugs. Anti-Cancer Drug Design, 10:361–372.
  • Chabner BA, Allegra CJ, Curt GA, Calabresi P. (1996). Goodman and Gilman’s The pharmacological basis of therapeutics, Antineoplastic agents. New York, U.S.A: McGraw-Hill, 1233–1257.
  • Carl PL, Chakravarty PK, Katzenellenbogen JA. (1981). A novel connector linkage applicable in prodrug design. J Med Chem, 24:479–480.
  • Connors TA. (1978). Antitumour drugs with latent activity. Biochemie, 60:979–987.
  • Bagshawe KD. (1989). The First Bagshawe lecture. Towards generating cytotoxic agents at cancer sites. Br J Cancer, 60:275–281.
  • Senter PD, Springer CJ. (2001). Selective activation of anticancer prodrugs by monoclonal antibody-enzyme conjugates. Adv Drug Deliv Rev, 53:247–264.
  • de Groot FM, Damen EW, Scheeren HW. (2001). Anticancer prodrugs for application in monotherapy: targeting hypoxia, tumor-associated enzymes, and receptors. Curr Med Chem, 8:1093–1122.
  • Springer CJ, Duvaz IN. (1996). Gene-directed enzyme prodrug therapy (GDEPT): Choice of Prodrugs. Adv Drug Delivery Rev, 22:351–364.
  • Harikrishna D, Raghavendra SN, Venkateshwarlu Y, Raghuram Rao A, Rama Krishna D. (2007). β-Galactoside prodrugs of doxorubicin for application in antibody directed enzyme prodrug therapy/prodrug monotherapy. Arch Pharm Res, 30:723–732.
  • Devalapally H, Rajan KS, Akkinepally RR, Devarakonda RK. (2008). Safety, pharmacokinetics and biodistribution studies of a beta-galactoside prodrug of doxorubicin for improvement of tumor selective chemotherapy. Drug Dev Ind Pharm, 34:789–795.
  • Ghosh AK, Khan S, David F. (1999). A β-galactoside phosphoramide mustard prodrug for use in conjunction with gene-directed enzyme prodrug therapy. Chem Commun, 2527–2528.
  • Ravindranathan KP, Harold JJ. (1990). A simplified one pot preparation of acetobromosugars from reduced sugars. J Carbohydrate Chem, 9:777–781.
  • Bollenback GN, Long JW, Benjamin DG, Lindquist JA. (1955). The synthesis of aryl-d-glucopyranosiduronic acids. J Am Chem Soc, 77, 3310–3315.
  • Leu YL, Chen CS, Wu YJ, Chern JW. (2008). Benzyl ether-linked glucuronide derivative of 10-hydroxycamptothecin designed for selective camptothecin-based anticancer therapy. J Med Chem, 51:1740–1746.
  • Vogel Brian, SF, Antony JH, Peter WGS, Austin RT. (1989). Vogel’s text book of practical organic chemistry. 5th ed. New York: Longman Scientific & technical, 960–975.
  • Ghosh AK, David F. (1997). A methyl glucuronate prodrug of phosphoramidic mustard. Tetrahedron Lett, 38:8795–8798.
  • David NP. (2011). AP5346 (ProLindac™), A DACH platinum polymer conjugate in phase II trials against ovarian cancer. Current Bioactive Compounds, 7:21–26.
  • David AW, Thomas LL. (2005). Foye’s Principles of medicinal chemistry, Cancer chemotherapy. 5th ed. India: Lippincott Williams & Wilkins, 924–950.
  • Ghosh AK, Khan S, Maini F, Nelson JA, David F. (2000). A daunorubicin β-galactoside prodrug for use in conjunction with gene directed enzyme prodrug therapy (GDEPT). Tetrahedron Lett, 41:4871–4874.
  • HariKrishna D, Rao AR, Krishna DR. (2003). Selective activation of anthracycline prodrugs for use in conjunction with ADEPT. Drug News Perspect, 16:309–318.
  • Boyer MJ, Tannock IF. (1993). Lysosomes, lysosomal enzymes, and cancer. Adv Cancer Res, 60:269–291.
  • Singh Y, Palombo M, Sinko PJ. (2008). Recent trends in targeted anticancer prodrug and conjugate design. Curr Med Chem, 15:1802–1826.
  • Chen Y, Hu L. (2009). Design of anticancer prodrugs for reductive activation. Med Res Rev, 29:29–64.
  • Greenwald RB, Pendri A, Conover CD, Lee C, Choe YH, Gilbert C et al. (1998). Camptothecin-20-PEG ester transport forms: the effect of spacer groups on antitumor activity. Bioorg Med Chem, 6:551–562.
  • Knox RJ, Connors TA. (1997). Prodrugs in Cancer Chemotherapy. Pathol Oncol Res, 3:309–324.
  • Dosio F, Stella B, Arpicco S, Cattel L. (2011). Macromolecules as taxane delivery systems. Expert Opin Drug Deliv, 8:33–55.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.